Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth Pharmaceuticals has signed leading image-related biomarker developer, VirtualScopics, to provide services for use in Wyeth's phase I clinical trial for an investigational new biopharmaceutical being studied as a potential treatment for muscle wasting conditions.
Subscribe to our email newsletter
Under the agreement, VirtualScopics, a provider of imaging solutions utilizing biomarkers for pharmaceutical development, will provide analytical and other imaging services to Wyeth for use in the trial.
“We appreciate the confidence that Wyeth has shown in VirtualScopics,” said Dr Stuart Shapiro, president and CEO of VirtualScopics. “Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies, and we are proud to have them as a client.”
VirtualScopics evolved from research initially undertaken at the University of Rochester Medical Center and School of Engineering. The biomedical company’s computer-assisted analysis technique provides superior precision and reproducibility, enabling faster and more reliable detection of disease progression or therapeutic benefit, accelerating the clinical trial process, and providing a basis for future diagnostic applications.